Objective: To observe the clinical efficacy of xuesaitong (XST) for coronary heart disease unstable angina with blood stasis

and investigate its effects on expression levels of hsa-miR-199a-5p

hsa-miR-146b-5p

KIR3DS1

HLA-DPB1

TP53SESN2

NCR1

and PRF1 in peripheral blood and to elucidate the molecular mechanism of XST for the coronary heart disease with blood stasis. Method: The 80 patients with coronary heart disease unstable angina grade Ⅰ-Ⅲ with blood stasis were enrolled and randomly divided into treatment group and control group (40 cases in each group). The patients in control group received routine western medicine and placebo

while the patients in treatment group also received XST capsules on the basis of routine western medicine therapy. The treatment duration was 4 weeks for both groups. The levels of total ischemic burden

seattle quality score for angina pectoris

haemo-dynamics and blood lipid were observed before and after treatment to evaluate the clinical of XST capsules for coronary heart disease unstable angina with blood stasis. Besides

hsa-miR-199a-5p

hsa-miR-146b-5p

KIR3DS1

HLA-DPB1

TP53

SESN2

NCR1

and PRF1 were validated by Real-time PCR. Result: As compared with control group

total ischemic burden

whole blood viscosity

plasma viscosity

red blood cell rigidity index

cholesterol (TC)

triglyceride(TG)

and low density lipoprotein cholesterol (LDL-C) were decreased in treatment group (P<0.05) after treatment; KIR3DS1

TP53

SESN2

PRF1 genes were up-regulated significantly while hsa-miR-199a-5p

hsa-miR-146b-5p levels were down-regulated in treatment group (P<0.05). Conclusion: XST could ease the symptoms of patients with coronary heart disease unstable angina with blood stasis and the underlying mechanism might be associated with hsa-miR-199a-5p and hsa-miR-146b-5p.